Patents by Inventor Allen John Lovey
Allen John Lovey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9580411Abstract: The invention is concerned with the compounds of formula (I): and salts thereof, wherein X, Y, Z, R1, R2, R3, R3?, R4, R5 and R6 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of Formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.Type: GrantFiled: March 27, 2015Date of Patent: February 28, 2017Assignee: Hoffmann-La Roche Inc.Inventors: Christine E. Brotherton-Pleiss, Huifen Chen, Shaoqing Chen, Zhi Chen, Shawn David Erickson, Anthony Estrada, Kyungjin Kim, Hongju Li, Allen John Lovey, Joseph P. Lyssikatos, Yimin Qian, Sung-Sau So, Peter Michael Wovkulich, Lin Yi
-
Publication number: 20150218141Abstract: The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Y, R1 and R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists of the TRPA1 channel and may be useful in treating inflammatory diseases and disorders associated with that channel.Type: ApplicationFiled: April 16, 2015Publication date: August 6, 2015Applicant: HOFFMANN-LA ROCHE INC.Inventors: Christine E. Brotherton-Pleiss, Zhi Chen, Shawn David Erickson, Kyungjin Kim, Hongju Li, Allen John Lovey, Yimin Qian, Sung-Sau SO, Peter Michael Wovkulich, Lin Yi
-
Publication number: 20150197509Abstract: The invention is concerned with the compounds of formula (I): and salts thereof, wherein X, Y, Z, R1, R2, R3, R3?, R4, R5 and R6 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of Formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.Type: ApplicationFiled: March 27, 2015Publication date: July 16, 2015Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC.Inventors: Christine E. BROTHERTON-PLEISS, Huifen CHEN, Shaoqing CHEN, Zhi CHEN, Shawn David ERICKSON, Anthony ESTRADA, Kyungjin KIM, Hongju LI, Allen John LOVEY, Joseph P. LYSSIKATOS, Yimin QIAN, Sung-Sau SO, Peter Michael WOVKULICH, Lin YI, I
-
Publication number: 20140148443Abstract: Disclosed are compounds of Formula I or pharmaceutically acceptable salts thereof, wherein X1, X2, X3, R1, R2 and R3 are as described in this application, and methods of using the compounds in the treatment of cancer.Type: ApplicationFiled: November 20, 2013Publication date: May 29, 2014Applicant: Hoffmann-La Roche Inc.Inventors: Xin-Jie Chu, Allen John Lovey, Binh Thanh Vu, Chunlin Zhao
-
Patent number: 8658646Abstract: The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.Type: GrantFiled: August 31, 2012Date of Patent: February 25, 2014Assignee: Hoffmann-LaRoche Inc.Inventors: Shaoqing Chen, Javier de Vicente Fidalgo, Matthew Michael Hamilton, Johannes Cornelius Hermann, Joshua Kennedy-Smith, Hongju Li, Allen John Lovey, Matthew C. Lucas, Kin-Chun Thomas Luk, Stephen M. Lynch, Counde O'yang, Fernando Padilla, Ryan Craig Schoenfeld, Achyutharao Sidduri, Michael Soth, Ce Wang, Peter Michael Wovkulich, Xiaohu Zhang
-
Patent number: 8618103Abstract: The present invention relates to the use of novel compounds of Formula I, wherein the variables m, n, p, q, Q, r, R, R?, X, X?, Y, Z1, Z2, and Z3 are defined as described herein, which inhibit JAK and are useful for the treatment of auto-immune and inflammatory diseases.Type: GrantFiled: September 9, 2010Date of Patent: December 31, 2013Assignee: Hoffmann-La Roche Inc.Inventors: Javier de Vicente Fidalgo, Johannes Cornelius Hermann, Remy Lemoine, Hongju Li, Allen John Lovey, Eric Brian Sjogren, Michael Soth
-
Patent number: 8513239Abstract: There are provided compounds of the formula or the pharmaceutically acceptable salts thereof, wherein X, Y, Z, V1, V2, R1, R2, R3, R4 and R5 are herein described. These compounds are useful as anticancer agents.Type: GrantFiled: October 9, 2008Date of Patent: August 20, 2013Assignee: Hoffmann-La Roche Inc.Inventors: David Joseph Bartkovitz, Jianping Cai, Xin-Jie Chu, Hongju Li, Allen John Lovey, Binh Thanh Vu, Chunlin Zhao
-
Publication number: 20130059834Abstract: The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.Type: ApplicationFiled: August 31, 2012Publication date: March 7, 2013Inventors: Shaoqing Chen, Javier de Vicente Fidalgo, Matthew Michael Hamilton, Johannes Cornelius Hermann, Joshua Kennedy-Smith, Hongju Li, Allen John Lovey, Matthew C. Lucas, Kin-Chun Thomas Luk, Stephen M. Lynch, Counde O'yang, Fernando Padilla, Ryan Craig Schoenfeld, Achyutharao Sidduri, Michael Soth, Ce Wang, Peter Michael Wovkulich, Xiaohu Zhang
-
Publication number: 20110059118Abstract: The present invention relates to the use of novel compounds of Formula I, wherein the variables m, n, p, q, Q, r, R, R?, X, X?, Y, Z1, Z2, and Z3 are defined as described herein, which inhibit JAK and are useful for the treatment of auto-immune and inflammatory diseases.Type: ApplicationFiled: September 9, 2010Publication date: March 10, 2011Inventors: Javier de Vicente Fidalgo, Johannes Cornelius Hermann, Remy Lemoine, Hongju Li, Allen John Lovey, Eric Brian Sjogren, Michael Soth
-
Patent number: 7851626Abstract: There is provided a compound of formula I and the pharmaceutically acceptable salts and esters thereof wherein X1, X2, R1, R2, R3, R4, R5 and R6 are herein described. The compounds exhibit activity as anticancer agents.Type: GrantFiled: November 27, 2006Date of Patent: December 14, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Qingjie Ding, Bradford James Graves, Norman Kong, Jin-Jun Liu, Allen John Lovey, Giacomo Pizzolato, John Lawson Roberts, Sung-Sau So, Binh Thanh Vu, Peter Michael Wovkulich
-
Patent number: 7705009Abstract: Novel 4-aminopyrimidine-5-thione derivatives are disclosed. These compounds inhibit cyclin-dependent kinases, in particular Cdk1, Cdk2 and Cdk4. These compounds and their pharmaceutically acceptable salts have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment or control of breast, lung, colon and prostate tumors.Type: GrantFiled: October 16, 2006Date of Patent: April 27, 2010Assignee: Hoffman-La Roche Inc.Inventors: Qingjie Ding, Nan Jiang, Allen John Lovey
-
Patent number: 7615634Abstract: Novel intermediate compounds are disclosed. These compounds are useful in the synthesis of 4-aminopyrimidine-5-one derivatives that inhibit cyclin-dependent kinases, in particular cyclin-dependent kinase 4 (Cdk4). The 4-aminopyrimidine-5-one derivatives and their pharmaceutically acceptable salts have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors.Type: GrantFiled: June 20, 2006Date of Patent: November 10, 2009Assignee: Hoffmann-La Roche Inc.Inventors: David Joseph Bartkovitz, Xin-Jie Chu, Qingjie Ding, Nan Jiang, Allen John Lovey, John Anthony Moliterni, John Guilfoyle Mullin, Jr., Binh Thanh Vu, Peter Michael Wovkulich
-
Publication number: 20090111789Abstract: There are provided compounds of the formula or the pharmaceutically acceptable salts thereof, wherein X, Y, Z, V1, V2, R1, R2, R3, R4 and R5 are herein described. These compounds are useful as anticancer agents.Type: ApplicationFiled: October 9, 2008Publication date: April 30, 2009Inventors: David Joseph Bartkovitz, Jianping Cai, Xin-Jie Chu, Hongju Li, Allen John Lovey, Binh Thanh Vu, Chunlin Zhao
-
Patent number: 7423051Abstract: Novel 2,6-diaminopyridine derivatives of formula wherein R1 and R2 are as defined below, are disclosed. These compounds inhibit cyclin-dependent kinases. These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment or control of breast, lung, colon and prostate tumors. Also disclosed are intermediates useful in the preparation of these novel 2,6-diaminopyridine derivatives.Type: GrantFiled: June 24, 2005Date of Patent: September 9, 2008Assignee: Hoffmann-La Roche Inc.Inventors: David Joseph Bartkovitz, Xin-Jie Chu, Allen John Lovey, Peter Michael Wovkulich
-
Patent number: 7423053Abstract: Novel 4-aminothiazole derivatives are disclosed. These compounds inhibit cyclin-dependent kinases. These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment or control of breast, lung, colon and prostate tumors. Also disclosed are intermediates useful in the preparation of these novel 4-aminothiazole derivatives.Type: GrantFiled: June 29, 2005Date of Patent: September 9, 2008Assignee: Hoffmann-La Roche Inc.Inventors: Li Chen, Xin-Jie Chu, Allen John Lovey, Chunlin Zhao
-
Patent number: 7211576Abstract: Novel diaminothiazoles of formula (I): are discussed. These compounds selectively inhibit the activity of Cdk4 and are thus useful in the treatment or control of cancer, in particular, the treatment or control of solid tumors. This invention also provides pharmaceutical compositions containing such compounds and methods of treating or controlling cancer, most particularly, the treatment or control of breast, lung, colon, and prostate tumors.Type: GrantFiled: April 4, 2005Date of Patent: May 1, 2007Assignee: Hoffmann-La Roche Inc.Inventors: Qingjie Ding, Nan Jiang, Kyungjin Kim, Allen John Lovey, Warren William McComas
-
Patent number: 7157455Abstract: Novel 4-aminopyrimidine-5-one derivatives are disclosed. These compounds inhibit cyclin-dependent kinases, in particular cyclin-dependent kinase 4 (Cdk4). These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment or control of breast, lung, colon and prostate tumors. Also disclosed are intermediates useful in the preparation of these novel 4-aminopyrimidine-5-one derivatives.Type: GrantFiled: February 2, 2004Date of Patent: January 2, 2007Assignee: Hoffmann-La Roche Inc.Inventors: David Joseph Bartkovitz, Xin-Jie Chu, Qingjie Ding, Nan Jiang, Allen John Lovey, John Anthony Moliterni, John Guilfoyle Mullin, Jr., Binh Thanh Vu, Peter Michael Wovkulich
-
Patent number: 6818663Abstract: The present invention is directed to novel diaminothiazoles of formula These compounds inhibit cyclin-dependent kinase 4 (Cdk4) and are selective against Cdk2 and Cdk1. These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment or control of breast, lung and colon and prostate tumors.Type: GrantFiled: May 5, 2003Date of Patent: November 16, 2004Assignee: Hoffmann-La RochesInventors: Xin-Jie Chu, Qingjie Ding, Nan Jiang, Kyungjin Kim, Allen John Lovey, Warren William McComas, John Guifoyle Mullin, Jr., Jefferson Wright Tilley
-
Publication number: 20040162303Abstract: Novel 4-aminopyrimidine-5-one derivatives are disclosed. These compounds inhibit cyclin-dependent kinases, in particular cyclin-dependent kinase 4 (Cdk4). These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment or control of breast, lung, colon and prostate tumors. Also disclosed are intermediates useful in the preparation of these novel 4-aminopyrimidine-5-one derivatives.Type: ApplicationFiled: February 2, 2004Publication date: August 19, 2004Inventors: David Joseph Bartkovitz, Xin-Jie Chu, Qingjie Ding, Nan Jiang, Allen John Lovey, John Anthony Moliterni, John Guilfoyle Mullin, Binh Thanh Vu, Peter Michael Wovkulich
-
Patent number: 6756374Abstract: Disclosed are novel diaminothiazoles of formula wherein R1, R2, R3, R4 and R5 are as herein disclosed. These compounds and their pharmaceutically acceptable salts and esters are selective inhibitors of Cdk4. As such, these compounds and their pharmaceutically acceptable salts and esters are anti-proliferative agents useful in the treatment or control of solid tumors, in particular breast, colon, lung and prostate tumors. Also disclosed are pharmaceutical compositions containing the compounds of formula I and their pharmaceutically acceptable salts and esters, as well as intermediates useful in the preparation of the compounds of formula I.Type: GrantFiled: January 9, 2002Date of Patent: June 29, 2004Assignee: Hoffmann-La Roche Inc.Inventors: Li Chen, Qingjie Ding, Paul Gillespie, Kyungjin Kim, Allen John Lovey, Warren William McComas, John Guilfoyle Mullin, Jr., Agostino Perrotta